Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Evaluation of the Effects of Anti-TNF Therapy on the Retina in Patients With Rheumatoid Arthritis and Ankylosing Spondylitis

10 november 2026 uppdaterad av: Muhammet Ali Gürsoy, Ankara City Hospital Bilkent

EVALUATION OF THE EFFECTS OF ANTI-TNF THERAPY ON THE RETINA IN PATIENTS WITH RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS

This prospective observational cohort study evaluates whether anti-tumor necrosis factor (anti-TNF) therapy changes the retinal and choroidal microvasculature and retinal structure in patients with rheumatoid arthritis (RA) or ankylosing spondylitis (AS). Patients for whom the rheumatology clinic decided to start anti-TNF therapy as part of routine care are compared with patients who continue treatment without anti-TNF agents. All participants undergo a complete eye examination, optical coherence tomography (OCT) and OCT angiography (OCTA) before treatment and at month 6. The main question is whether retinal vessel density changes differently over time between the two groups.

Studieöversikt

Status

Avslutad

Intervention / Behandling

Detaljerad beskrivning

Background: Chronic systemic inflammation in RA and AS has been associated with endothelial dysfunction and microvascular changes. TNF-alpha is a key mediator of this inflammation, and anti-TNF agents are widely used in both diseases. Prospective data on retinal and choroidal microvasculature with measurements taken before the start of anti-TNF therapy are limited.

Design and participants: Patients with RA or AS followed at the Rheumatology Clinic of Ankara Bilkent City Hospital were referred to the Ophthalmology Clinic between October and December 2025. Treatment decisions were made by the treating rheumatologists, independently of the study. The anti-TNF group consists of anti-TNF-naive patients for whom anti-TNF therapy was planned; their baseline examination was performed before the first dose. The control group consists of patients who were not receiving anti-TNF therapy at baseline and did not start it during the 6-month follow-up.

Assessments: At baseline and month 6, all participants undergo best-corrected visual acuity (logMAR), Goldmann applanation tonometry, slit-lamp biomicroscopy and dilated fundus examination with a +90 D lens. OCT (Heidelberg Spectralis) is used to measure central and sectoral macular thickness, peripapillary retinal nerve fiber layer (RNFL) thickness (global and six sectors) and ganglion cell layer (GCL) thickness. OCTA (RTVue XR Avanti with AngioVue, Optovue) is performed with fovea-centred 6x6 mm scans. Superficial (SCP) and deep capillary plexus (DCP) vessel density are recorded for the whole image, superior and inferior hemifields, and foveal, parafoveal and perifoveal regions with four sectors. Foveal avascular zone (FAZ) area, FAZ perimeter, acircularity index, foveal vessel density and choriocapillaris flow area are also recorded. 3D projection artifact removal is applied. Scans with a quality (Q) score below 6, significant motion or projection artifacts, or segmentation errors are excluded. All examinations are performed by the same, unmasked examiner. ESR and CRP values closest to each visit are obtained from hospital records.

Statistical analysis: Eye-level data are analysed with linear mixed models adjusted for age and sex. The treatment effect is assessed by the group-by-time interaction. The study is reported according to the STROBE guideline.

Studietyp

Observationell

Inskrivning (Faktisk)

53

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 75 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Testmetod

Icke-sannolikhetsprov

Studera befolkning

Adult patients with rheumatoid arthritis or ankylosing spondylitis followed at the Rheumatology Clinic of Ankara Bilkent City Hospital and referred to the Ophthalmology Clinic between October and December 2025.

Beskrivning

Inclusion Criteria:

  • Age 18 to 75 years
  • Diagnosis of rheumatoid arthritis or ankylosing spondylitis
  • Receiving treatment for RA or AS (conventional therapy, planned initiation of anti-TNF therapy, or continued conventional non-biologic therapy)
  • Willingness to participate and written informed consent

Exclusion Criteria:

  • • History of retinal disease (e.g., diabetic retinopathy, age-related macular degeneration, retinal vein occlusion)

    • Ocular disease that may affect OCT measurements or visual field, such as glaucoma, optic neuropathy or dense cataract
    • Uveitis, diabetes mellitus or systemic hypertension
    • Previous ocular surgery or laser treatment, or high refractive error
    • Pregnancy or breastfeeding
    • Treatment with non-TNF biologic agents (e.g., abatacept, rituximab)
    • OCTA scan quality (Q) score below 6

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiv: PROSPECTIVE

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
Anti-TNF group

Anti-TNF-naive patients with RA or AS for whom the treating rheumatologist planned to start anti-TNF therapy as part of routine care. The baseline examination was performed before the first dose.

adalimumab, etanercept, golimumab

Andra namn:
  • TNF inhibitor prescribed by the treating rheumatologist according to routine clinical practice; not assigned by the study protocol.
Control group

Patients with RA or AS who were not receiving anti-TNF therapy at baseline and did not start it during the 6-month follow-up. They continued conventional (non-biologic) treatment.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change in superficial capillary plexus whole-image vessel density
Tidsram: Baseline and month 6

SCP vessel density (%) in fovea-centred 6x6 mm OCTA scans (AngioVue, Optovue). Change from baseline to month 6 is compared between groups (group-by-time interaction).

Baseline and month 6
Change in deep capillary plexus whole-image vessel density
Tidsram: Baseline and month 6

DCP vessel density (%) in fovea-centred 6x6 mm OCTA scans. Change from baseline to month 6 is compared between groups.

Baseline and month 6

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Erythrocyte sedimentation (mm/h) rate
Tidsram: Baseline and month 6

Change in systemic inflammatory marker obtained from hospital records.

Baseline and month 6
C-reactive protein (mg/L) value
Tidsram: Baseline and month 6

Change in systemic inflammatory marker obtained from hospital records.

Baseline and month 6

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Studierektor: Yasin Toklu, Professor Doctor, Ankara City Hospital Bilkent

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

25 november 2025

Primärt slutförande (Faktisk)

23 juni 2026

Avslutad studie (Faktisk)

23 juni 2026

Studieregistreringsdatum

Först inskickad

18 oktober 2026

Först inskickad som uppfyllde QC-kriterierna

10 november 2026

Första postat (Faktisk)

12 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

12 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

10 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

IPD-planbeskrivning

Individual participant data will not be shared publicly. Aggregate results will be reported in scientific publications.

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

produkt tillverkad i och exporterad från U.S.A.

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera